 | | | | Alnylam Pharmaceuticals Inc's gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition. | | |
| | | The Sackler family - owners of Purdue Pharma - transferred more than $10 billion in a decade from the OxyContin maker to its trusts and holding companies, the New York Times reported on Monday, citing a new audit commissioned by the drugmaker. | | |
| | | (Reuters Health) - Male scientists are more likely than their female counterparts to use superlatives like "first" or "novel" to describe their work, a new study suggests, and this disparity might contribute to other professional gender gaps, the authors say. | | |
| | | GlaxoSmithKline said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson and Genmab's Darzalex. | | |
| | | Using e-cigarettes significantly increases the risk of developing chronic lung conditions such as asthma or emphysema, U.S. researchers said on Monday. | | |
| | | (Reuters Health) - (Reuters Health) - People who eat lots of ultra-processed foods are more likely to develop diabetes than those whose diets contain more foods found in nature, a new study suggests. | | |
| | | (Reuters Health) - In a little over a decade, the number of patients in the U.S. with primary care providers dropped by 2%, a new study finds. | | |
| | | The U.S. government said on Monday the deadline for signing-up for 2020 insurance plans under the Affordable Care Act (ACA) has been extended by three days to Dec. 18 to accommodate those who experienced issues while attempting to enroll. | | |
| | | Ibrahim Ali al-Jadari's four teenage daughters lie at home on intravenous drips that will soon run out as they, like tens of thousands of other Yemenis, battle a seasonal surge of dengue fever. | | |
| | | Bayer AG on Monday said it has asked a U.S. federal appeals court to throw out a $25 million judgment it was ordered to pay to a California man who blamed the company's Roundup weed killer for his cancer. | | |
| | | BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa's approval to treat patients with mantle cell lymphoma, who have received at least one prior therapy. | | |
|
| |
